Basis: Four-quarter operating cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The operating cash flow yield is N/A as of 2026-10-06T22:43:17.190Z.
Calculation as of: 2026-10-06T22:43:17.190Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 426cd0b806ab2bb4e1acb1d630c97f0b27e7b6ad30a760f07fb4e7b3f4328ff8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
OPERATING CASH FLOW YIELD
N/A
Market Cap
$5.32M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.35M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.24M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.22M
Operating Cash Flow Yield
N/A
TTM Avg
17.61%
3Y Avg
17.61%
5Y Avg
17.61%
Market Cap
$5.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.21M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.12M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.63M
Operating Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | OPERATING CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Soligenix, Inc. (SNGX) | $5.31M | N/A | N/A | N/A | N/A |
| Gelteq Limited Ordinary Shares (GELS)vs › | $5.32M | N/A | N/A | N/A | N/A |
| Lexaria Bioscience Corp. (LEXX)vs › | $5.35M | N/A | N/A | N/A | N/A |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.24M | N/A | N/A | N/A | N/A |
| Pulmatrix, Inc. (PULM)vs › | $5.22M | N/A | 17.61% | 17.61% | 17.61% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Alzamend Neuro Inc (ALZN)vs › | $5.21M | N/A | N/A | N/A | N/A |
| Lunai Bioworks Inc. (LNAI)vs › | $5.12M | N/A | N/A | N/A | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.63M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $4.97M | N/A | N/A | N/A | N/A |
OCF Yield = TTM Operating Cash Flow / Market Cap
Operating cash flow yield is the inverse of P/OCF, expressing trailing operating cash flow as a percentage of price. It sits between earnings yield (before non-cash accrual effects) and FCF yield (before capital expenditure).
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
